Considering the CHAPTER-1 study results, how does deucrictibant's efficacy in reducing HAE attack rates compare to current prophylactic treatments, and what implications does this have for patient care?

With deucrictibant showing positive results over a 12-week period, what are your thoughts on its long-term safety and tolerability for chronic use in HAE patients?

How do the improvements in attack severity and reduction in on-demand medication usage, as seen with deucrictibant, translate into overall health-related quality of life for HAE patients?

Based on the Phase 1 trial data of STAR-0215, how significant is the potential for 3- to 6-month dosing intervals in the management of HAE, and what benefits might this offer to patients?

How does the efficacy of STAR-0215, in terms of kallikrein inhibition and attack prevention, compare to existing treatments like Takhzyro (lanadelumab)?

Given the varying dosing schedules of deucrictibant and STAR-0215, how might these treatments enable more personalized approaches to HAE management?

With the upcoming data from the ALPHA-STAR trial for STAR-0215, what are the key aspects or potential outcomes that healthcare professionals are most anticipating?

Following the FDA’s lifting of the clinical hold on deucrictibant and the fast track designation for STAR-0215, what are the next steps in the regulatory process, and how might these developments affect patient access to these treatments?